NCT01869725View on ClinicalTrials.gov

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

April 1, 2013

Primary Completion Date

December 26, 2018

Study Completion Date

December 26, 2018

Conditions
Adult MedulloblastomaChildhood MedulloblastomaNeuroblastomaNeuroendocrine TumorSomatostatinoma
Interventions
DRUG

gallium Ga 68-edotreotide

Given IV

PROCEDURE

positron emission tomography/computed tomography

Undergo gallium Ga 68-edotreotide PET/CT scan

RADIATION

indium In 111 pentetreotide

Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan

PROCEDURE

computed tomography

Undergo indium In 111 pentetreotide contrast-enhanced CT scan

PROCEDURE

contrast-enhanced magnetic resonance imaging

Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sue O'Dorisio

OTHER

NCT01869725 - Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | Biotech Hunter | Biotech Hunter